Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Background Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but systematic assessments of their effects have not been performed. Montanide ISA-51, an incomplete Freund’s adjuvant (IFA), is used in many vaccine trials, but concerns have been raised about negative effects in mu...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Ileana S Mauldin, Marit M Melssen, Stephen Turner, Pankaj Kumar, Karlyn E Pollack, Max O Meneveau, Kevin T Lynch, Alexander F Koeppel, Samuel J Young, Katia Sol-Church, Craig L Slingluff Jr
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-05-01
Online Access:	https://jitc.bmj.com/content/8/1/e000544.full